Press "Enter" to skip to content

Triplet Combination With Vorinostat Shows High Response Rate in Frontline MCL – Targeted Oncology

admin 0

Triplet Combination With Vorinostat Shows High Response Rate in Frontline MCL  Targeted Oncology

A combination of vorinostat, cladribine, and rituximab demonstrated high, durable rates of complete response in patients with previously untreated mantle cell …

“lymphoma cancer” – Google News

(Visited 4 times, 1 visits today)

Leave a Reply

Your email address will not be published. Required fields are marked *